# Xiamen AmonMed Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xiamen-amonmed-biotechnology-co

- Industry: Biotechnology
- Headquarters: Xiamen, China
- Website: www.amonmed.com
- Latest round: Series A (Aug 1, 2018)
- Investors on record: 1

## About

Based in Xiamen, China, and founded in 2014, Xiamen AmonMed Biotechnology Co., Ltd. operates as a high-tech enterprise, specializing in the development, production and sales of nano-fluorescence immunoassay analyzers and supporting kits, and also providing third-party medical testing services. In 2019, the company has obtained ISO 13485:2016 registration certification and in 2021 its product COVID-19 Antigen Schnelltest Kit certificated by BfArM Germany.

The company has gained 12 patents in medical area. And there are 38 in vitro diagnostic reagents in the company, and 34 products of the company passed the EU CE certification. The company's products can be categorized into three different categories which are POCT instrument, fluorescence immunization  and colloidal gold. Products within incudes AFS-1000 and AFS-2000A dry fluorescence immunoassay analyzers, COVID-19 Neutralizing Antibody Test Kit, COVID-19 Antigen Rapid Test Kit, COVID-19 IgM/IgG Test Kit and COVID-19/ Influenza A/ Influenza B Virus Antigen Assay Kit.

## Funding rounds

- Series A, Aug 1, 2018 — Cybernaut Investment Group

## Investors

- Cybernaut Investment Group (https://capitalatlas.ai/funds/cybernaut-investment-group) — Series A